News

PeptidPro company is engaged in research and production of fundamentally new medical and parapharmaceutical products of a new class of drugs – peptide bioregulators

Clinical study phase IIa of experimental vaccine UB-311 against Alzheimer’s disease
18 January 2019
United Neuroscience (United Neuroscience) has announced positive results from a clinical trial of phase IIa of the experimental vaccine UB-311 against Alzheimer's disease.

01.2019. United Neuroscience (United Neuroscience) has announced positive results from a clinical trial of phase IIa of the experimental vaccine UB-311 against Alzheimer’s disease. According to the company, a synthetic PEPTIDA vaccine that targets beta-amyloid in patients who were given it for a long time using two different schemes, reached its primary end points in a double-blind, placebo-controlled study of safety and immunogenicity. Source: PharmaTimes, http://www.pharmatimes.com/